FDA grants orphan drug designation to CervoMed’s dementia drug
Neflamapimod is an oral investigational small-molecule drug designed to treat frontotemporal dementia.
Neflamapimod is an oral investigational small-molecule drug designed to treat frontotemporal dementia.
High-level results from an ongoing clinical trial make Astrazeneca’s combination treatment the first to show benefit in a subtype of prostate cancer.
A conversation with Steve Rosenberg, CEO of uMotif electronic clinical outcome assessment (eCOA) - collecting data electronically.
Neural Ice: Is this long-lasting pain therapy revolutionizing treatment?
The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.
The European Commission has approved Pfizer’s treatment for adults and adolescents with severe hemophilia A or B.
From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of resilience and curiosity.
Muvalaplin significantly lowered lipoprotein(a) levels, reducing the risk of cardiovascular events in high-risk adults.
Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to type 2 diabetes in 99% of participants.
Traditional clinical trials usually rely on several physical trial sites to recruit and monitor patients.
Driven by the effects of the COVID-19 pandemic, the market for decentralized clinical trials has seen a push that will lead it to more than triple in size within the next decade.
The partners will work together to make Medable’s digital and decentralized clinical trial platform available on Google Cloud Marketplace.
A recent Lindus Health survey emphasizes the importance of patient-centered designs in clinical trials, particularly highlighting how telehealth options could improve accessibility and convenience for participants.
Gifthealth Partners with United Digestive to boost patient access and procedure prep.
In a conversation with Professor Jennifer Visser-Rogers, chief scientific officer at Coronado Research, she shares insights on the evolving landscape of pharmaceutical development.
Abbisko’s small molecule drug pimicotinib has smashed the primary goal of a phase 3 trial for the treatment of tenosynovial giant cell tumor (TGCT), taking the asset a step further to the market in China and elsewhere.
Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the acquisition of Avid Bioservices.
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Innovative radiotherapy offers a precision treatment alternative.
Scemblix is the first drug to show superiority over all standard of care therapies for a rare type of leukemia.
Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and obese adults with heart disease.
The Boston-based startup Axonis Therapeutics has bagged $115 million in a Series A round to fuel its pipeline of treatments for pain, epilepsy and other conditions.
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their own versions of these highly coveted drugs.
Vicky Marriott’s journey from enjoying school math to heading a global team of statisticians at Phastar reveals her belief in the power of empathy and collaboration.
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of its cost-effectiveness.
The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.
The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.
From exploring the wonders of plants as a curious teen to leading global initiatives at SCIEX, Gitte Barknowitz has carved out an exciting and unconventional career in science.
At the forefront of precision dosing, Sharmeen leads DoseMe's efforts to transform personalized medicine from lab research to bedside application.
Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization of innovative cellular therapies.
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a first-in-class treatment for obesity.
The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.
Outsourcing Pharma sat down ahead of CPHI with Dr Andreas Raabe, CEO of Adragos Pharma, to explore the evolving world of pharmaceutical outsourcing.
Patient recruitment is a critical and often challenging aspect of clinical trials, particularly for biopharmaceutical companies seeking to accelerate drug development.
Rebekah's father passed on his passion for science and problem solving to her and much of her childhood was spent doing fun hands-on activities from taking apart household mechanics to building rockets.
The proceeds of the financing will support the development of LoQus23’s lead candidate, a small molecule inhibitor that is expected to enter the clinic in 2026.
CPHI 2024
At this October’s CPHI event being held in Milan, dsm-firmenich, is inviting stakeholders across the pharmaceutical market to immerse themselves in its patient-inspired innovations.
The Barcelona-based startup Sequentia Biotech has raised €10 million ($11 million) in a Series A round to finance the development of its omics-based technology for use in biomedicine, agritech and food.
Joaquima Guix Salichs is the director of engineering and extraction technology at Bioiberica, where she leads a team of scientists focused on advancing extraction methods and solving large-scale industrial challenges.
The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and halted clinical trials of the drug as data indicate a high risk of severe adverse events.
The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for the treatment of the rare disease Niemann-Pick disease type C (NPC), which until now has lacked FDA-approved therapies.
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met its primary endpoint.
The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, shortly after successfully completing a first phase 1 clinical trial.
Alison has more than 35 years of broad experience delivering clinical trials to sponsors with a patient centric mindset.
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.
Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have confidence and answer hard questions.
Clinical trials are becoming increasingly complex as emerging technologies such as immunotherapy enter the mainstream.
Recent investments by major pharmaceutical companies signal a growing confidence in artificial intelligence’s (AI's) potential to transform drug development.